Kiadis Poised To Launch Lead Product ATIR101 In 2019
Launch approval of Netherlands-based Kiadis Pharma's lead asset ATIR101 looks likely in Europe by early-2019 for safer, more effective bone marrow transplants. US approval will take longer.
You may also be interested in...
October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.
Gesynta’s SEK190m ($20m) private placement allows its lead asset to enter Phase IIa studies for treating chronic inflammatory conditions in certain systemic sclerosis patients.
An expanded $120m series C financing will help Freeline advance its lead program in hemophilia B into a pivotal trial next year, CEO Theresa Heggie tells Scrip.